Explore GPCR-targeting therapies and their untapped potential in drug development, making up 30-35 percent of approved drugs.

Historically, GPCRs have been one of the most important targets for drug discovery. In fact, around 30 % of all currently marketed drugs target GPCRs. Despite this, a significant number of GPCRs ...

Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ...

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Partnership combines AbTherx's proprietary Atlas Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / AC ...

Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and ...

The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and ...